Otsuka’s Phase 3 Trial for AVP-786 Fails in Treating Agitation in Alzheimer’s Patients
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka Pharmaceutical Co. Ltd. have announced that their phase 3 clinical trial for the drug AVP-786 has not met the primary efficacy endpoint in treating agitation in patients with Alzheimer’s disease.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
